Biotech stocks are generally extremely volatile, and the ARK Genomic Revolution ETF (ARKG) proves it. The biotech-heavy fund has declined more than 50% year-to-date, compared to the S&P 500 (SPX), which has dropped 20% year-to-date. However, not all biotech stocks are highly volatile. In this video, we look at a particular biotech stock that could add stability to your portfolio in a recession. The company has many FDA-approved products and numerous product candidates in the pipeline. It has a huge cash reserve, putting it in a position to continue to fund the development of its products.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.